← Rolf Wachter

Papers by Rolf Wachter

Page 4 · newest first

151. Early insights into the characteristics and evolution of clinical parameters in a cohort of patients prescribed sacubitril/valsartan in GermanyPostgraduate Medicine · 2018
152. Rationale and Design of TRANSITION: A Randomized Trial of Pre-Discharge vs. Post-Discharge Initiation of Sacubitril/ValsartanESC Heart Failure · 2017
153. Amount or Intensity? Potential Targets of Exercise Interventions in Patients with Heart Failure with Preserved Ejection FractionESC Heart Failure · 2017
154. Impact of Systolic Blood Pressure on the Safety and Tolerability of Initiating and Up-Titrating Sacubitril/Valsartan in Patients with Heart Failure and Reduced Ejection Fraction: Insights from the TITRATION StudyENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) · 2017
155. Right Heart Dysfunction and Failure in Heart Failure with Preserved Ejection Fraction: Mechanisms and Management. Position Statement on Behalf of the Heart Failure Association of the European Society of CardiologyEuropean Journal of Heart Failure · 2017
156. Relevance of supraventricular runs detected after cerebral ischemiaNeurology · 2017
157. Incidence of Previously Undiagnosed Atrial Fibrillation Using Insertable Cardiac Monitors in a High-Risk PopulationJAMA Cardiology · 2017
158. Atrial fibrillation in retinal vascular occlusion disease and non-arteritic anterior ischemic optic neuropathyPLoS ONE · 2017
159. Exercise Training in Diastolic Heart Failure (Ex-DHF): Rationale and Design of a Multicentre, Prospective, Randomized, Controlled, Parallel Group TrialEuropean Journal of Heart Failure · 2017
160. Screening for Atrial FibrillationCirculation · 2017
161. Prognostic impact of diastolic dysfunction in systolic heart failure—A cross‐project analysis from the German Competence Network Heart FailureClinical Cardiology · 2017
162. Large-scale genome-wide analysis identifies genetic variants associated with cardiac structure and functionJournal of Clinical Investigation · 2017
163. Arterial stiffness and elevated left ventricular filling pressure in patients at risk for the development or a previous diagnosis of HF—A subgroup analysis from the DIAST-CHF studyJournal of the American Society of Hypertension · 2017
164. Heart Failure Awareness Survey in Germany: General Knowledge on Heart Failure Remains PoorESC Heart Failure · 2017
165. Baseline Demographics, Safety, and Patient Acceptance of an Insertable Cardiac Monitor for Atrial Fibrillation Screening: The REVEAL-AF StudyJournal of Atrial Fibrillation · 2017
166. The role of atrial fibrillation in patients with an embolic stroke of unknown source (ESUS)Thrombosis and Haemostasis · 2017
167. Association between Embolic Stroke Patterns, ESUS Etiology, and New Diagnosis of Atrial Fibrillation: A Secondary Data Analysis of the Find-AF TrialStroke Research and Treatment · 2017
168. An exploratory propensity score matched comparison of second-generation and first-generation baroreflex activation therapy systemsJournal of the American Society of Hypertension · 2016
169. Apixaban for treatment of embolic stroke of undetermined source (ATTICUS randomized trial): Rationale and study designInternational Journal of Stroke · 2016
170. Pulmonary hypertension in heart failure with preserved ejection fraction: a plea for proper phenotyping and further research†European Heart Journal · 2016
171. [Invasive treatment of hypertension : Update 2016].Der Internist · 2016
172. Ghrelin and Hormonal Markers Under Exercise Training in Patients with Heart Failure with Preserved Ejection Fraction: Results from the Ex-DHF Pilot StudyESC Heart Failure · 2016
173. Late outcomes after acute pulmonary embolism: rationale and design of FOCUS, a prospective observational multicenter cohort studyJournal of Thrombosis and Thrombolysis · 2016
174. Effect of Escitalopram on All-Cause Mortality and Hospitalization in Patients With Heart Failure and DepressionJAMA · 2016
175. Heart Failure Epidemiology 2000–2013: Insights from the German Federal Health Monitoring SystemEuropean Journal of Heart Failure · 2016
176. Initiating Sacubitril/Valsartan (LCZ696) in Heart Failure: Results of TITRATION, a Double-Blind, Randomized Comparison of Two Uptitration RegimensENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) · 2016
177. Baroreflex activation therapy in patients with prior renal denervationJournal of Hypertension · 2016
178. Effects of Baroreflex Activation Therapy on Ambulatory Blood Pressure in Patients With Resistant HypertensionHypertension · 2016
179. Early pneumonia and timing of antibiotic therapy in patients after nontraumatic out-of-hospital cardiac arrestCritical Care · 2016
180. Surgical Experience and Long-term Results of Baroreflex Activation Therapy for Heart Failure With Reduced Ejection FractionSeminars in Thoracic and Cardiovascular Surgery · 2016
181. Tolerability and Feasibility of Beta-Blocker Titration in HFpEF Versus HFrEFJACC Heart Failure · 2015
182. Left ventricular heart failure and pulmonary hypertensionEuropean Heart Journal · 2015
183. Risk stratification of normotensive pulmonary embolism: prognostic impact of copeptinEuropean Respiratory Journal · 2015
184. Elevated Plasma C-Terminal Endothelin-1 Precursor Fragment Concentrations Are Associated with Less Anxiety in Patients with Cardiovascular Risk Factors. Results from the Observational DIAST-CHF StudyPLoS ONE · 2015
185. Natriuretic peptides for the detection of paroxysmal atrial fibrillationOpen Heart · 2015
186. Baroreflex Activation Therapy for the Treatment of Heart Failure with a Reduced Ejection Fraction: Safety and Efficacy in Patients with and without Cardiac Resynchronization TherapyEuropean Journal of Heart Failure · 2015
187. Baroreflex Activation Therapy for the Treatment of Heart Failure With a Reduced Ejection FractionJACC Heart Failure · 2015
188. Determinants of Submaximal Exercise Capacity in Patients at Risk for Heart Failure with Preserved Ejection Fraction—results from the DIAST-CHF StudyESC Heart Failure · 2015
189. Galectin-3 in Patients with Heart Failure with Preserved Ejection Fraction: Results from the Aldo-DHF TrialEuropean Journal of Heart Failure · 2014
190. Increase of angiotensin II type 1 receptor auto-antibodies in Huntington’s diseaseMolecular Neurodegeneration · 2014
191. Effects of baroreflex activation therapy on arterial stiffness and central hemodynamics in patients with resistant hypertensionJournal of Hypertension · 2014
192. Effects of Long-Term Endurance and Resistance Training on Diastolic Function, Exercise Capacity, and Quality of Life in Asymptomatic Diastolic Dysfunction vs. Heart Failure with Preserved Ejection FractionESC Heart Failure · 2014
193. Effects of long-term endurance and resistance training on diastolic function, exercise capacity, and quality of life in asymptomatic diastolic dysfunction vs. heart failure with preserved ejection fractionESC Heart Failure · 2014
194. Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: The Randomized Double-Blind Reminder StudyEuropean Heart Journal · 2014
195. Effects of exercise training on different quality of life dimensions in heart failure with preserved ejection fraction: the Ex-DHF-P trialEuropean Journal of Preventive Cardiology · 2014
196. Impact of Baroreflex Activation Therapy on Renal Function - A Pilot StudyAmerican Journal of Nephrology · 2014
197. Improved Detection of Silent Atrial Fibrillation Using 72-Hour Holter ECG in Patients With Ischemic StrokeStroke · 2013
198. Differential interaction of clinical characteristics with key functional parameters in heart failure with preserved ejection fraction — Results of the Aldo-DHF trialInternational Journal of Cardiology · 2013
199. Cost-effectiveness of 7-day-Holter monitoring alone or in combination with transthoracic echocardiography in patients with cerebral ischemiaClinical Research in Cardiology · 2013
200. Bile acids induce arrhythmias in human atrial myocardium—implications for altered serum bile acid composition in patients with atrial fibrillationHeart · 2013